HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

[Drug therapy for corneo-conjunctival neoplasm].

AbstractBACKGROUND:
The goal of therapy for corneo-conjunctival neoplasm is lesion removal, with the most widespread procedure being complete tumor resection with or without associated chemotherapy lines. As this sort of procedure entails a high relapse rate (9-52%) the use of adjuvant therapies to reduce the occurence of relapse becomes a need. The administration of a number of topically administered drugs has been used for adjuvant therapy, including mitomycin C, 5-fluorouracil and interferon a 2b.
OBJECTIVE:
To determine the clinical experience published regarding the effectiveness of the various drug therapies for cor-neo-conjunctival neoplasm.
SEARCH STRATEGY:
Information reported on this topic in the Medline database (1966-2004) was searched using corneo-conjunctival neoplasm, 5-fluorouracil, mitomycin C, and interferon ca2b as key words.
SELECTION CRITERIA:
All papers quoting dosage for drugs used,treatment length, adverse effect development, and clinical response obtained were included.
PRIMARY RESULTS:
Papers reporting the use of 5-fluorouracil re few when compared to those quoting other drugs, with a response rate of 88% and a relapse rate of 20%. The use of mitomycin C is widely described in the medical literature with a response rate of 90% and a relapse rate of 13%, but in association with the development of adverse effects in a high percentage of patients. Interferon ca 2b is the last drug to be incorporated in the treatment of these ocular lesions, with a response rate of 100% and a low incidence of adverse effects, with a relapse rate of 4%.
CONCLUSIONS:
Mitomycin C is an effective drug, but its use is associated with a high number of adverse events, some of which may lead to therapy discontinuation. Interferon ct 2b has efficacy outcomes comparable to mitomycin C and a lower incidence of adverse effects, which are mostly mild in nature. The use of 5-fluorouracil is relegated to a second-tier status.
AuthorsA Murcia López, J Borrás Blasco, M C Alvarado Valero, A Navarro Ruiz, M González Delgado, J J Martínez Toldos
JournalFarmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria (Farm Hosp) Vol. 29 Issue 2 Pg. 126-33 (Mar 2005) ISSN: 1130-6343 [Print] Spain
Vernacular TitleTratamiento farmacológico de la neoplasia corneal y conjuntival.
PMID16013935 (Publication Type: English Abstract, Journal Article, Review)
Chemical References
  • Antineoplastic Agents
Topics
  • Antineoplastic Agents (therapeutic use)
  • Chemotherapy, Adjuvant (methods)
  • Clinical Trials as Topic
  • Conjunctival Neoplasms (drug therapy)
  • Humans

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: